PolyCore Therapeutics LLC is a drug development company spinout from Drexel University focused on development of products for CNS disorders.

PolyCore Therapeutics LLC is a drug development company spinout from Drexel University focused on development of products for CNS disorders. The initial product in development, PCT-3010, is a biased signaling D3 agonist, a breakthrough once-a-day oral therapy for Parkinson’s disease that improves motor symptoms without development of drug tolerance or dyskinesia. The product will be utilized as monotherapy or as an adjunct to L-dopa to prolong the efficacy time of L-dopa and reduce L-dopa induced dyskinesia. This is a six billion per year market opportunity in the US.
Industry: Health
Status: Active

Contact Information

http://www.polycoretherapeutics.com/

jim.harris648@gmail.com

Jim Harris

Co-Founder & CEO

Sandhya Kortagere

Co-Founder & CSO

Mike Saporito

COO